Azd9668    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症5

299. 嚢胞性線維症 [臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 1,592 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-001530-27-GB
(EUCTR)
11/03/200918/04/2008A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic FibrosisA Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic Fibrosis Cystic Fibrosis
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis
Product Name: AZD9668
Product Code: AZD9668
INN or Proposed INN: none
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
70Phase 2Germany;United Kingdom;Denmark;Sweden
2EUCTR2008-001530-27-DK
(EUCTR)
02/02/200920/11/2008A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic FibrosisA Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic Fibrosis Cystic Fibrosis
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis
Product Name: AZD9668
Product Code: AZD9668
INN or Proposed INN: none
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
70Phase 2Germany;United Kingdom;Denmark;Sweden
3NCT00757848
(ClinicalTrials.gov)
October 200822/9/2008A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic FibrosisA Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients With Cystic FibrosisCystic FibrosisDrug: AZD9668;Drug: AZD9668 Placebo equivalentAstraZenecaNULLCompleted16 YearsN/AAll56Phase 2Denmark;Germany;Poland;Russian Federation;Sweden;United Kingdom
4EUCTR2008-001530-27-SE
(EUCTR)
06/08/200817/06/2008A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic FibrosisA Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic Fibrosis Cystic Fibrosis
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis
Product Name: AZD9668
Product Code: AZD9668
INN or Proposed INN: none
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
70Phase 2Germany;United Kingdom;Denmark;Sweden
5EUCTR2008-001530-27-DE
(EUCTR)
08/07/200826/05/2008A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic FibrosisA Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic Fibrosis Cystic Fibrosis
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis
Product Name: AZD9668
Product Code: AZD9668
INN or Proposed INN: none
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
65Phase 2United Kingdom;Germany;Denmark;Sweden